Skip to main content

PharmAust Health Care

$0.075 (0%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
24 June 2026 at 1:43am
Register to track PAA and receive email alerts.
PAA Announcements on Price Chart

Latest Announcements

Headline Date
Results of General Meeting 30 June 2023 at 1:00pm
Trading Halt 30 June 2023 at 10:15am
General Meeting - Chairman Script 30 June 2023 at 10:10am
Motor Neurone Disease Phase 1/2 Clinical Trial Update 27 June 2023 at 8:40am
Commencement of Cohort 3 in Phase 1/2 MND Trial 9 June 2023 at 10:15am
PharmAust MND Trial Interim Analysis PK Outcomes 7 June 2023 at 10:00am
Trading Halt 5 June 2023 at 10:05am
Notice of General Meeting/Proxy Form 26 May 2023 at 1:40pm
Motor Neurone Disease Clinical Trial Update 22 May 2023 at 9:55am
Securities issued under LR7.1 & LR7.1A 16 May 2023 at 12:10pm
Progress update on Phase 1/2 MND interim analysis 16 May 2023 at 8:55am
Application for quotation of securities - PAA 11 May 2023 at 3:50pm
Cancel - Notification regarding unquoted securities - PAA 11 May 2023 at 3:50pm
Notification regarding unquoted securities - PAA 11 May 2023 at 9:55am
Terms & Conditions of Unlisted Options 11 May 2023 at 9:50am
Appendix 3Y 11 May 2023 at 9:45am
Section 708(5) Notice 11 May 2023 at 9:45am
Notification regarding unquoted securities - PAA 11 May 2023 at 9:30am
Notification regarding unquoted securities - PAA 11 May 2023 at 9:15am
Application for quotation of securities - PAA 11 May 2023 at 9:10am
Independent tests show MPL retains long-term shelf-life 10 May 2023 at 8:45am
MPL has anti-cancer effects across multiple cancer types 9 May 2023 at 8:40am
Proposed issue of securities - PAA 3 May 2023 at 10:30am
PharmAust Raises $2.5m via Placement 3 May 2023 at 10:30am
Appendix 4C and Quarterly Update 28 April 2023 at 6:50pm
Trading Halt 28 April 2023 at 6:45pm
MND Trial Successfully Completes Second Patient Cohort 28 April 2023 at 8:55am
Canine Trial Update 21 April 2023 at 8:40am
Arrival of additional MPL tablets 17 April 2023 at 8:50am
PharmAust launches international CEO search 13 April 2023 at 8:50am
MND Trial Completes Enrolment of Cohort 2 30 March 2023 at 9:40am
Stable Patient in MND trial reaches 6-months on MPL 28 March 2023 at 9:50am
PharmAust Investor Webinar Presentation 16 March 2023 at 8:35am
AOG Energy Conference Presentation 15 March 2023 at 8:00pm
Investor Webinar 14 March 2023 at 11:00am
Correction to Appendix 3Y 13 March 2023 at 5:40pm
Change of Director's Interest Notice 13 March 2023 at 10:05am
Canine Cancer Trial Update 7 March 2023 at 8:40am
Interim analysis recommended in MND trial 2 March 2023 at 8:35am
European Patent relating to MPL Combinations in Cancer 28 February 2023 at 8:20am
Appendix 4D & Half Year Report 27 February 2023 at 4:35pm
First Patient of Cohort 2 Dosed in MND Trial 20 February 2023 at 8:30am
PharmAust canine trial update 10 February 2023 at 10:15am
Appendix 4C and Quarterly Update 30 January 2023 at 4:10pm
PharmAust Progresses to Elevated Doses in MND Patients 20 January 2023 at 8:45am
Change of Director's Interest Notice 10 January 2023 at 5:05pm
MND Trial Successfully Completes First Patient Cohort 6 January 2023 at 9:35am
PharmAust Canine Trial Update clarification 20 December 2022 at 1:25pm
PharmAust Canine Trial Update 20 December 2022 at 8:45am
PharmAust Receives R&D Tax Incentive Refund 12 December 2022 at 9:35am
Register to track PAA and receive email alerts.